JPWO2019232425A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019232425A5 JPWO2019232425A5 JP2020567078A JP2020567078A JPWO2019232425A5 JP WO2019232425 A5 JPWO2019232425 A5 JP WO2019232425A5 JP 2020567078 A JP2020567078 A JP 2020567078A JP 2020567078 A JP2020567078 A JP 2020567078A JP WO2019232425 A5 JPWO2019232425 A5 JP WO2019232425A5
- Authority
- JP
- Japan
- Prior art keywords
- ggggs
- seq
- antigen recognition
- recognition domain
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 description 30
- 102000036639 antigens Human genes 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 30
- 108020001507 fusion proteins Proteins 0.000 description 18
- 102000037865 fusion proteins Human genes 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 239000012634 fragment Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679597P | 2018-06-01 | 2018-06-01 | |
| US62/679,597 | 2018-06-01 | ||
| PCT/US2019/034981 WO2019232425A1 (en) | 2018-06-01 | 2019-05-31 | Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021525530A JP2021525530A (ja) | 2021-09-27 |
| JPWO2019232425A5 true JPWO2019232425A5 (enExample) | 2022-06-30 |
Family
ID=68696762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567078A Pending JP2021525530A (ja) | 2018-06-01 | 2019-05-31 | キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200054675A1 (enExample) |
| EP (1) | EP3802578A4 (enExample) |
| JP (1) | JP2021525530A (enExample) |
| CN (1) | CN112533942A (enExample) |
| WO (1) | WO2019232425A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| JP2020530454A (ja) | 2017-08-07 | 2020-10-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 安全な細胞治療薬を生成するためのプラットフォーム |
| CA3101505A1 (en) * | 2018-05-31 | 2019-12-05 | Washington University | Chimeric antigen receptor t cells (car-t) for the treatment of cancer |
| JP2022516389A (ja) * | 2018-05-31 | 2022-02-28 | ワシントン・ユニバーシティ | 血液悪性腫瘍を治療するためのゲノム編集インバリアントナチュラルキラーＴ（ｉＮＫＴ）細胞 |
| EP3802578A4 (en) | 2018-06-01 | 2022-03-23 | Washington University | SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| US11786553B2 (en) | 2019-03-01 | 2023-10-17 | Allogene Therapeuctics, Inc. | Chimeric cytokine receptors bearing a PD-1 ectodomain |
| WO2021127261A1 (en) * | 2019-12-17 | 2021-06-24 | The General Hospital Corporation | Engineered immune cells with reduced toxicity and uses thereof |
| EP3845646A1 (en) * | 2019-12-30 | 2021-07-07 | Secarna Pharmaceuticals GmbH & Co. KG | Modified antisense oligonucleotide for inhibition of foxp3 expression |
| AU2021227191A1 (en) * | 2020-02-24 | 2022-08-25 | Allogene Therapeutics, Inc. | BCMA car-T cells with enhanced activities |
| AU2021251113A1 (en) * | 2020-04-06 | 2022-10-27 | Celledit Llc | Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling |
| CN111548420B (zh) * | 2020-05-14 | 2021-10-15 | 深圳普瑞金生物药业有限公司 | 一种抗间皮素嵌合抗原受体、表达基因、表达载体、t细胞及其用途 |
| WO2022098756A1 (en) * | 2020-11-03 | 2022-05-12 | WUGEN, Inc. | Chimeric antigen receptor cell therapy |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN112876535B (zh) * | 2021-02-08 | 2023-06-30 | 浙江华缔药业集团医药开发有限公司 | 生物活性多肽及其应用 |
| CN118056012B (zh) * | 2021-08-24 | 2025-05-30 | 赛斯尔擎生物技术（上海）有限公司 | 一种修饰细胞的方法 |
| CN114410686B (zh) * | 2021-12-24 | 2023-10-03 | 武汉大学 | 一种工程化外泌体原位纳米疫苗及其制备方法和应用 |
| WO2023225249A1 (en) * | 2022-05-20 | 2023-11-23 | President And Fellows Of Harvard College | Methods and compositions relating to treatment of cns diseases |
| CN116102662A (zh) * | 2022-10-10 | 2023-05-12 | 武汉波睿达生物科技有限公司 | 一种靶向ca9的融合嵌合抗原受体、重组表达载体及其应用 |
| JP2025535448A (ja) * | 2022-10-20 | 2025-10-24 | マイクロ クリスパー プライベート リミテッド | 免疫療法におけるサイトカイン放出症候群の軽減 |
| AU2023362750A1 (en) * | 2022-10-20 | 2025-06-05 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| CN116240173B (zh) * | 2023-02-02 | 2024-09-27 | 西安电子科技大学 | 一种冷热肿瘤调控型car-单核/巨噬细胞及其制备方法和应用 |
| CN117164712B (zh) * | 2023-02-22 | 2024-05-24 | 成都优赛诺生物科技有限公司 | 一种靶向cd22的单域抗体、嵌合抗原受体及其应用 |
| WO2025077790A1 (en) * | 2023-10-11 | 2025-04-17 | Chengdu Ucello Biotechnology Co., Limited | Engineered immune cells and uses thereof |
| CN117186202B (zh) * | 2023-11-08 | 2024-02-02 | 北京大学第三医院（北京大学第三临床医学院） | 一种新细胞因子csbf及其在干眼治疗中的应用 |
| CN117866110B (zh) * | 2023-12-27 | 2024-06-11 | 广东唯泰生物科技有限公司 | 一种靶向flt-3的第四代嵌合抗原受体及其应用 |
| CN119345372A (zh) * | 2024-10-28 | 2025-01-24 | 北京大学人民医院 | Cd132在治疗aml中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2778701T3 (es) | 2012-07-13 | 2020-08-11 | The Trustees Of The Univ Of Pennsylvania Center For Technology Transfer | Gestión de toxicidad para la actividad antitumoral de CAR |
| WO2015066262A1 (en) * | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| HRP20201906T1 (hr) | 2013-12-20 | 2021-04-02 | Fred Hutchinson Cancer Research Center | Označene kimerne efektorske molekule i njihovi receptori |
| EP3243831A1 (en) * | 2014-02-27 | 2017-11-15 | Ucl Business Plc | Variants of the proliferation-inducing ligand (april) |
| ES2926384T3 (es) * | 2015-02-06 | 2022-10-25 | Nat Univ Singapore | Métodos para mejorar la eficacia de células inmunitarias terapéuticas |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2017112877A1 (en) | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| US11111505B2 (en) * | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| CA3020923A1 (en) * | 2016-04-15 | 2017-10-19 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| WO2018064602A1 (en) * | 2016-09-30 | 2018-04-05 | Baylor College Of Medicine | Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease |
| CN106636090B (zh) * | 2016-10-11 | 2019-08-09 | 上海优卡迪生物医药科技有限公司 | 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用 |
| WO2018073393A2 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| WO2018073391A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| CA3048648A1 (en) * | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | T cells expressing a chimeric antigen receptor |
| US10870703B2 (en) * | 2017-10-02 | 2020-12-22 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
| JP7621795B2 (ja) | 2017-10-19 | 2025-01-27 | セレクティス | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
| AU2018370217A1 (en) | 2017-11-17 | 2020-05-28 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for alleviating Cytokine Release Syndrome |
| EP3802578A4 (en) | 2018-06-01 | 2022-03-23 | Washington University | SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY |
-
2019
- 2019-05-31 EP EP19810633.8A patent/EP3802578A4/en not_active Withdrawn
- 2019-05-31 WO PCT/US2019/034981 patent/WO2019232425A1/en not_active Ceased
- 2019-05-31 US US16/428,362 patent/US20200054675A1/en not_active Abandoned
- 2019-05-31 CN CN201980044894.5A patent/CN112533942A/zh active Pending
- 2019-05-31 JP JP2020567078A patent/JP2021525530A/ja active Pending
-
2022
- 2022-05-17 US US17/746,645 patent/US12304941B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019232425A5 (enExample) | ||
| JP7140861B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| US5837821A (en) | Antibody construct | |
| JP5376759B2 (ja) | 二重特異性抗体 | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| Zuo et al. | An efficient route to the production of an IgG-like bispecific antibody | |
| CARTER et al. | Toward the production of bispecific antibody fragments for clinical applications | |
| Mertens | Tribodies: fab–scfv fusion proteins as a platform to create multifunctional pharmaceuticals | |
| JP2020503885A5 (enExample) | ||
| JP2017521998A (ja) | 新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法 | |
| JP2022009816A5 (enExample) | ||
| IL276903B1 (en) | Bispecific egfr/cd16 antigen-binding protein | |
| TWI690539B (zh) | 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用 | |
| CN115066274A (zh) | 三价结合分子 | |
| WO2022166728A1 (zh) | 双特异性抗体 | |
| US20130165629A1 (en) | Bispecific t-cell activator antibody | |
| JPWO2021184673A5 (enExample) | ||
| JPWO2019232409A5 (enExample) | ||
| JPWO2020252366A5 (enExample) | ||
| Noor et al. | Production of a mono-biotinylated EGFR nanobody in the E. coli periplasm using the pET22b vector | |
| JPWO2019175368A5 (enExample) | ||
| JPWO2021163299A5 (enExample) | ||
| JPWO2021127184A5 (enExample) | ||
| CN111448214A (zh) | 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)的小型化抗体、其聚合物及应用 | |
| JPWO2020087065A5 (enExample) |